Data Validates Acuvue Abiliti 1‑Day Myopia Efficacy

The data provides further validation of Acuvue Abiliti 1‑Day’s efficacy as a myopia management tool, showing that 55.2% of children wearing Abiliti 1‑Day showed no clinically meaningful myopia progression^* over three years,^{^1} and mean axial elongation was reduced by 0.31 mm, on average, over three-years.^¥1

55.2% of children wearing Abiliti 1‑Day showed no clinically meaningful myopia progression^* over three years

Acuvue Abiliti 1‑Day features novel RingBoost technology² with non-coaxial optics –a deliberate departure from traditional multifocal/dual focus approaches. By creating myopic retinal defocus off the line of sight, the design includes two stronger treatment zones (+7D) plus a central boost (+10D) while maintaining visual quality.² Clinical trial data show over 95% of children achieved 6/6 vision or better while wearing the lens,^§3 addressing a key clinician concern: efficacy should not come at the cost of everyday visual function.

Comfort Leads to Compliance

Efficacy matters, but compliance is decisive: in practice, a myopia intervention only works if the child consistently wears it for the prescribed duration. Abiliti 1‑Day – the first daily‑disposable silicone‑hydrogel soft contact lens specifically designed to slow myopia progression in children^‡2 – is engineered to support that real‑world use: its smaller diameter improves handling, insertion and removal,^†4 and it is made from the same material (senofilcon A) as Acuvue Oasys 1-Day, which has never been beaten in comfort in six clinical studies posted on ClinicalTrials.govμ.

According to Johnson and Johnson Vision data on file, a randomised crossover trial comparing MiSight 1 Day with Abiliti 1‑Day found:

• 90.8% of children reported they never or rarely could feel the lens on their eyes while wearing Abiliti 1-Day, compared to 69.7% for MiSight 1 Day.^#5
• 89.2% of children agreed the Abiliti 1-Day lens was easy to put in the eyes, compared to 53% for MiSight 1 Day.^#5
• 93.8% of children agreed that Abiliti 1-Day lens were easy to take out of the eyes, compared to 77.3% for MiSight 1 Day lens.^#5
• 95.4% of children reported they never or rarely experienced Abiliti 1-Day lens moving out of place or falling out, compared to 66.7% for MiSight 1 Day lens.^#5

As well as efficacy and comfort, Johnson and Johnson said the Abiliti 1-Day lens meets growing family expectations for effective, low‑burden treatments that fit seamlessly into school, sports and everyday life; again supporting sustained wear and better long‑term outcomes.

Optometrists wishing to be trained to fit Abiliti 1-Day lenses must complete the Acuvue Abiliti 1 Day Accreditation Program on JNJVisionPro or contact their Johnson and Johnson Vision representative.

Footnotes

^* Change in spherical equivalent of cycloplegic auto refraction ≥-0.25 D.

^{^} Over the course of three years compared to only 13.2% of those wearing a single vision, regular contact lens.

^¥ Compared to a single vision, regular contact lens after three years of wear.

• Measured using LogMAR visual acuity where 0.00 LogMAR is equivalent to 20/20 vision.

^‡ Based on publicly available information as of 3 December 2021.

^† JJV Data on File 2021. Top 3 box = Extremely easy, Very easy, Easy.

^μ ClinicalTrials.gov is a website maintained by the United States National Institutes of Health. The six clinical studies evaluated subjective comfort as a primary or secondary endpoint for Acuvue Oasys 1-Day with HydraLuxe technology brand family contact lenses vs. competitors’ products. Review conducted as of 31 October 2025.

# Based on descriptive summaries of top two box (never/rarely) responses at two weeks in a randomised, controlled, crossover study (n = 75; intention-to-treat population; ages 7–17 years with sphere refraction: -1.00 to -4.50 D, with ≤ 0.75 D astigmatism in each eye).

References

1. JJV data on file. Efficacy of Acuvue Abiliti 1-Day soft therapeutic lenses for myopia management: Comparative claims vs. single vision and dual focus lenses.
2. JJV data on file 2021. Development of optical design of Acuvue Abiliti 1-Day soft therapeutic lenses for myopia management.
3. JJV data on file 2021. Stand-alone performance claims – Acuvue Abiliti 1-Day soft therapeutic lenses for myopia management.
4. JJV data on file 2021. Mechanical design of Acuvue Abiliti 1-Day soft therapeutic lenses for myopia management – Effect on fit and handling.
5. JJV data on file.